Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment.

about

Efficacy and safety of apatinib in patients with previously treated metastatic colorectal cancer: a real-world retrospective study.Comparison of apatinib and capecitabine (Xeloda) with capecitabine (Xeloda) in advanced triple-negative breast cancer as third-line therapy: A retrospective study

P2860

Q55130826-990568DF-2BCA-4C67-9797-A896107CB1E6 Q58759141-AADBF040-5D39-43E5-A250-A98C6D64A952

P2860

Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment.

Item

http://www.wikidata.org/entity/Q47339196

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Apatinib for metastatic breast ...... ous anti-angiogenic treatment.

@en

Apatinib for metastatic breast ...... ous anti-angiogenic treatment.

@nl

type

Item

label

Apatinib for metastatic breast ...... ous anti-angiogenic treatment.

@en

Apatinib for metastatic breast ...... ous anti-angiogenic treatment.

@nl

prefLabel

Apatinib for metastatic breast ...... ous anti-angiogenic treatment.

@en

Apatinib for metastatic breast ...... ous anti-angiogenic treatment.

@nl

P1476

Apatinib for metastatic breast ...... ous anti-angiogenic treatment.

@en

P2093

Biyun Wang

http://www.w3.org/2001/XMLSchema#string

Jian Zhang

http://www.w3.org/2001/XMLSchema#string

Jun Cao

http://www.w3.org/2001/XMLSchema#string

Leiping Wang

http://www.w3.org/2001/XMLSchema#string

Xichun Hu

http://www.w3.org/2001/XMLSchema#string

Ying Lin

http://www.w3.org/2001/XMLSchema#string

Zheng Wu

http://www.w3.org/2001/XMLSchema#string

Zhonghua Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Safety and pharmacokinetics of novel selective vascular endothelial growth factor receptor-2 inhibitor YN968D1 in patients with advanced malignancies

Apatinib (YN968D1) reverses multidrug resistance by inhibiting the efflux function of multiple ATP-binding cassette transporters

Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer

Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis

Phase II open-label study of sunitinib in patients with advanced breast cancer.

Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple-negative breast cancer.

Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial.

Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer.

Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer.

Multicenter phase II study of apatinib in non-triple-negative metastatic breast cancer

P304

1010428317711033

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1010428317711033

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28639910

http://www.w3.org/2001/XMLSchema#string

Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment.

about

P2860

P2860

Apatinib for metastatic breast cancer in non-clinical trial setting: Satisfying efficacy regardless of previous anti-angiogenic treatment.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698